Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Biol Chem
Glavni autori: Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Biochemistry and Molecular Biology 2017
Teme:
Immunology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://ncbi.nlm.nih.gov/pubmed/28438838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.776476
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items